Generics BulletinWith US trade tariffs continuing to loom large over the pharma industry, Organon CEO Kevin Ali touched on the subject with respect to the firm’s biosimilars business during the company’s recent first-
Pink SheetThe European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc
ScripDozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,